Abstract

Glaucoma affects approximately 80 million individuals worldwide, a condition for which current treatment options are inadequate. The primary risk factor for glaucoma is elevated intraocular pressure. Intraocular pressure is determined by the balance between the secretion and outflow of aqueous humor. Here we show that using the RNA interference tool CasRx based on shH10 adenovirus-associated virus can reduce the expression of the aqueous humor circulation related genes Rock1 and Rock2, as well as aquaporin 1 and β2 adrenergic receptor in female mice. This significantly reduced intraocular pressure in female mice and provided protection to the retina ganglion cells, ultimately delaying disease progression. In addition, we elucidated the mechanisms by which the knockdown of Rock1 and Rock2, or aquaporin 1 and β2 adrenergic receptor in female mice, reduces the intraocular pressure and secures the retina ganglion cells by single-cell sequencing.

The primary risk factor for glaucoma is elevated intraocular pressure. Here, the authors show that AAV-delivered CasRx to reduce the expression of Rock1 and Rock2 as well as Aqp1 and Adrb2 can significantly reduce intraocular pressure, ultimately delaying glaucoma progression in mice.

Details

Title
CRISPR-CasRx-mediated disruption of Aqp1/Adrb2/Rock1/Rock2 genes reduces intraocular pressure and retinal ganglion cell damage in mice
Author
Yao, Mingyu 1   VIAFID ORCID Logo  ; Zeng, Zhenhai 1 ; Li, Siheng 2 ; Zou, Zhilin 3 ; Chen, Zhongxing 1 ; Chen, Xinyi 3 ; Gao, Qingyi 1   VIAFID ORCID Logo  ; Zhao, Guoli 1 ; Chen, Aodong 3 ; Li, Zheng 3 ; Wang, Yiran 1 ; Ning, Rui 1 ; McAlinden, Colm 4   VIAFID ORCID Logo  ; Zhou, Xingtao 1 ; Huang, Jinhai 1   VIAFID ORCID Logo 

 Chinese Academy of Medical Sciences, Eye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University; NHC Key laboratory of Myopia and Related Eye Diseases; Key Laboratory of Myopia and Related Eye Diseases, Shanghai, China (GRID:grid.506261.6) (ISNI:0000 0001 0706 7839); Shanghai Research Center of Ophthalmology and Optometry, Shanghai, China (GRID:grid.411079.a) (ISNI:0000 0004 1757 8722) 
 Chinese Academy of Medical Sciences, Eye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University; NHC Key laboratory of Myopia and Related Eye Diseases; Key Laboratory of Myopia and Related Eye Diseases, Shanghai, China (GRID:grid.506261.6) (ISNI:0000 0001 0706 7839); Wenzhou Medical University, School of Ophthalmology and Optometry and Eye Hospital, Wenzhou, China (GRID:grid.268099.c) (ISNI:0000 0001 0348 3990) 
 Wenzhou Medical University, School of Ophthalmology and Optometry and Eye Hospital, Wenzhou, China (GRID:grid.268099.c) (ISNI:0000 0001 0348 3990) 
 Chinese Academy of Medical Sciences, Eye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University; NHC Key laboratory of Myopia and Related Eye Diseases; Key Laboratory of Myopia and Related Eye Diseases, Shanghai, China (GRID:grid.506261.6) (ISNI:0000 0001 0706 7839); Queen Victoria Hospital, Corneo Plastic Unit & Eye Bank, East Grinstead, UK (GRID:grid.439490.3) (ISNI:0000 0004 0400 3188) 
Pages
6395
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3086183621
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.